A Multiple Ascending Dose Study of COR388

Alzheimer Disease Clinical Trial

Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease

Status Completed

Clinical Trial Summary

The study is a randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety and tolerability of ascending repeat doses of COR388 HCl in older healthy male and female subjects and a cohort of Alzheimer's disease subjects.

Clinical Trial Description

The study will enroll 3 cohorts of 8 healthy subjects ≥55 and ≤80 years of age at the Clinical Pharmacology Unit (CPU) and 1 cohort of 12 AD subjects ≥55 and ≤80 years of age. Subjects in cohorts 1-3 will receive the study drug or placebo for 10 consecutive days while confined to the CPU. AD patients in cohort 4 will receive the study drug or placebo for 28 days as outpatient. Blood samples samples will be collected for pharmacokinetic measurements. ;

Related Conditions & MeSH terms

• Alzheimer Disease

• NCT number: NCT03418688
• Study type: Interventional
• Source: Cortexyme Inc.
• Status: Completed
• Phase: Phase 1
• Start date: March 6, 2018
• Completion date: October 15, 2018